PEG-MGF vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PEG-MGF
PEG-MGF (PEGylated Mechano Growth Factor) is a variant of IGF-1 that is produced in response to muscle damage. PEGylation extends its half-life from minutes to several hours, making it practical for use.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | PEG-MGF | Cagrilintide |
|---|---|---|
| Mechanism | Activates muscle satellite cells (stem cells) and promotes their fusion to existing muscle fibers for repair and growth. MGF is produced naturally in response to mechanical stress on muscles. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Research protocols typically use 200-400mcg injected into targeted muscle groups 2-3 times weekly, usually post-workout. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Intramuscular injection, ideally into muscles trained that day. Best administered post-workout when satellite cell activation is relevant. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Injection site soreness, potential hypoglycemia, and localized swelling. Generally well-tolerated. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |